# Evaluate the Effect of Vimseltinib on Pharmacokinetics of Combined Oral Contraceptive (Ethinyl Estradiol/Levonorgestrel)

> **NCT07539090** · PHASE1 · RECRUITING · sponsor: **Deciphera Pharmaceuticals, LLC** · enrollment: 24 (estimated)

## Conditions studied

- Healthy Participants

## Interventions

- **DRUG:** Vimseltinib
- **DRUG:** Combined Oral Contraceptive (COC) (ethinyl estradiol [EE]/levonorgestrel [LNG])

## Key facts

- **NCT ID:** NCT07539090
- **Lead sponsor:** Deciphera Pharmaceuticals, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-05
- **Primary completion:** 2026-06
- **Final completion:** 2026-06
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2026-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07539090

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07539090, "Evaluate the Effect of Vimseltinib on Pharmacokinetics of Combined Oral Contraceptive (Ethinyl Estradiol/Levonorgestrel)". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT07539090. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*